Determination of status in neoplastic disease
AssigneeThe Regents of the University of California
InventorsDennis J. Slamon, William L. McGuire
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Regents of the University of California
InventorsDennis J. Slamon, William L. McGuire
Estimating the term…
Amplification of the HER-2/neu oncogene is related to the status of neoplastic diseases, particularly breast and ovarian adenocarcinomas. The presence of multiple gene copies in tumor cells indicates that the disease is more likely to spread beyond the primary tumor site, and that the disease therefore may require more aggressive treatment than might otherwise be indicated by other diagnostic factors. In particular, the degree of gene amplification appears to provide greater prognostic utility than either the estrogen receptor or the progesterone receptor, and provides utility equal to that of the determination of lymph node status. The information provided by the gene amplification test, however, is not duplicative with the determination of lymph node status and the two tests together provide greatly improved prognostic utility.
A method for screening patients to determine disease status, said method comprising:
A method for determining a prognosis in patients suffering from breast or ovarian adenocarcinoma, said method comprising:
A method for determining the proper course of treatment for patients suffering from breast or ovarian adenocarcinoma, said method comprising:
Dependencies are inferred from the claim text.